SCI时时刷

search
+
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with my...
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
Multiple myeloma (MM) flourishes within the bone marrow (BM), a metabolicall...
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intens...
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Extramedullary disease (EMD) in multiple myeloma (MM) affects up to 20% of p...
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
The TRB repertoire was characterized in 137 samples, representing 59 patients from the HOVON-139/GIVE trial at trial entry...
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
Competing interests The author discloses the following relationships: Cons...
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosoma...
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/ref...
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Competing interests F.M. reports honoraria from Therakos/Mallinckrodt, Jan...
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and rel...
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis...
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities a...
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a kind of aggressive T-cell lymphoma with significant enrichment of non-malig...
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity
The role of the bone marrow (BM) microenvironment in regulating the antitumor immune response in Waldenstrom macroglobulin...
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
Mantle cell lymphoma (MCL) is a currently incurable lymphoma subtype, with m...
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
This study aimed to provide real-world evidence on progression risk in patients with high-risk smoldering multiple myeloma...
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple mye...
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigms for hematological malignancies. ...
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
Histologic transformation (HT) of indolent non-Hodgkin lymphoma (iNHL) to diffuse large B-cell lymphoma (DLBCL) carries a ...
Molecular monitoring in CML—a modern example of an old proverb
“You cannot see the forest for the trees” (John Haywood, London 1546) Chro...
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
Multiple myeloma (MM) is a plasma cell (PC) disorder characterized by skeletal involvement at the time of diagnosis. Recen...
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/fail...
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplif...
Indolent nodal T follicular helper cell lymphomas—A case series
Indolent nodal T follicular helper cell lymphomas—A case series
Angioimmunoblastic T-cell lymphoma (AITL) originates from T follicular helper (TFH) cells and is wide...
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. C...
RSK1 dependency in FLT3-ITD acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Internal tandem duplications (ITD) in fms-like tyrosine kinase 3 (FLT3) represent the most common genetic alteration in de...
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philade...
What have we learned about TP53-mutated acute myeloid leukemia?
What have we learned about TP53-mutated acute myeloid leukemia?
TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 m...
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
In recent years, Venetoclax (Ven) has gained a prominent position in the treatment of newly diagnosed...
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts
Complex karyotype (CK), occurring in 10–15% of adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cases...
阅读更多
format_indent_increase